Agenus Inc. Stock price

Equities

AGEN

US00847G7051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.58 USD +4.24% Intraday chart for Agenus Inc. +4.58% -29.94%
Sales 2024 * 279M Sales 2025 * 199M Capitalization 233M
Net income 2024 * -162M Net income 2025 * -285M EV / Sales 2024 * 0.84 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.17 x
P/E ratio 2024 *
-1.36 x
P/E ratio 2025 *
-0.81 x
Employees 389
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.73%
1 week+0.32%
Current month-16.96%
1 month-28.46%
3 months-30.08%
6 months-52.44%
Current year-32.79%
More quotes
1 week
0.53
Extreme 0.525
0.58
1 month
0.49
Extreme 0.485
0.78
Current year
0.49
Extreme 0.485
0.95
1 year
0.49
Extreme 0.485
2.13
3 years
0.49
Extreme 0.485
6.79
5 years
0.49
Extreme 0.485
6.79
10 years
0.49
Extreme 0.485
10.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 94-03-30
Director of Finance/CFO 58 95-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 71 94-03-30
Director/Board Member 66 16-05-16
Director/Board Member 71 20-10-07
More insiders
Date Price Change Volume
24-03-28 0.58 +4.24% 5 508 167
24-03-27 0.5564 +3.73% 3,681,348
24-03-26 0.5364 -3.94% 5,159,745
24-03-25 0.5584 +2.25% 5,366,077
24-03-22 0.5461 -2.86% 5,118,735

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company's antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5564 USD
Average target price
5.5 USD
Spread / Average Target
+888.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Agenus Inc. - Nasdaq